linjc16/ctgov huggingface dataset:
Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management

Study Overview
=================
Brief Summary
-----------------
Comparing the effectiveness of Ivermectin( IVM) +Hydroxychloroquin + azithromycin (AZT) group to Hydroxychloroquin (HCQ) + azithromycin (AZT)

Detailed Description
-----------------
Comparing effectiveness of single dose 0.2mg/kg Ivermectin (IVM) plus hydroxychloroquine (HCQ) 400mg BID in first day then 200mg BID for 5 days plus azithromycin (AZT) 500mg in first day then 250mg for 5 days. The comparison group was a historical control population and data collected from the current study were compared to that historical control population

Official Title
-----------------
Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (An Externally Controlled Pilot Trial)

Conditions
-----------------
COVID 19

Intervention / Treatment
-----------------
* Drug: Ivermectin (IVM)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -1. Patients with age above 18 years and any gender with definite Dx of covid19 and pneumonia in the ward according to the clinical, laboratory, and imaging criteria. 2. Understands and agrees to comply with planned study procedures. Exclusion Criteria: Patients with hypersensitivity or severe adverse effects to Ivermectin Renal impairment Hepatic impairment. Pregnancy or a desire to become pregnant (drug considered pregnancy category c) Breast feeding. Patient with covid 19 positive and mild no pneumonia Children under the age of five or those who weigh less than 15 kilograms

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT)<br>Ivermectin 12 mg /weekly )+ Hydroxychloroquine 400mg/daily + azithromycin 500mg daily | Drug: Ivermectin (IVM)<br>* Ivermectin 0.2 mg /kg (single dose at once =2 tablets of 6mg/weekly<br>* Other names: Ivermectin;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Cured Patients | Primary outcome is assessed by calculating the number of patients who had symptoms free and two successive readings of negative PCR swab. | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to Cure of COVID-19 Patients in the IVM +HCQ+AZT Group | Time to cure is evaluated by measuring time from admission of the patient to the hospital till discharge after being free of symptoms and negative PCR swab. Once nasopharyngeal and oropharyngeal swab viral PCR testing yielded negative results 2 times consecutively, no further testing was performed | 4 week |
Omega-3 Fatty Acid Supplementation in Older Adults

Study Overview
=================
Brief Summary
-----------------
The purpose of this study to determine whether Fish oil (Omega-3 Fatty Acid) supplementation has an impact on inflammation and lean body mass in older adults. The investigators expect that Fish oil supplementation will reduce inflammation and prevent the loss of lean mass compared to placebo.

Official Title
-----------------
The Impact of Omega-3 Fatty Acid Supplementation on Markers of Inflammation and Lean Body Mass in Older Adults

Conditions
-----------------
Inflammation

Intervention / Treatment
-----------------
* Dietary Supplement: Omega-3 fatty acid
* Dietary Supplement: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 60 years of age or over Exclusion Criteria: Fish, seafood allergies, nut allergies, soy allergies Habitual (>1/week) fish or seafood consumption Current Omega-3 supplement use Gastrointestinal problems Current anti-inflammatory medication use Current anticoagulant medication use

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Fish oil (Omega-3 fatty acid)<br>2 capsules/day of ProOmega providing 650mg EPA and 450mg DHA | Dietary Supplement: Omega-3 fatty acid<br>* Omega-3 fatty acid, Eicosapentaenoic acid+docosahexaenoic acid in capsule form<br>* Other names: ProOmega (Nordic Naturals);|
| Placebo Comparator: Soybean oil<br>2 capsules/day | Dietary Supplement: Placebo<br>* Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| C-Reactive protein | Inflammatory marker | At baseline testing and at 3 month endpoint | 
| IL6 | Inflammatory cytokine | At baseline and at 3 month endpoint | 
| TNFα | Inflammatory cytokine | At baseline and at 3 month endpoint | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Skeletal muscle mass/body composition | The amount of skeletal muscle mass and fat mass and their ration will be determined. | At baseline testing and at 3 month endpoint | 
| Lower body muscular strength | Measurement of maximum strength in the leg press exercise | At baseline and at 3 month endpoint | 
| Upper body muscular strength | Measurement of maximum strength in the chest press exercise | At baseline and at 3 month endpoint | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Omega-3 fatty acid, Fish oil, Muscle mass, Muscle strength, Older adults, Circulating inflammatory cytokines, Skeletal muscle mass, Upper body strength, Lower body strength
Neuroaxial Blokade and Blood Pressure

Study Overview
=================
Brief Summary
-----------------
The effect of individualized fluid optimization during neuroaxial blockade has not been evaluated. The investigators evaluated if if Stroke decrease 15 min after activation of neuroaxial blockade and whether SV could be optimized to pre activation values.

Detailed Description
-----------------
The purpose of this study is to evaluate SV maximization with aid of the LiDCO system which is a minimal invasive technique only requiring a venous and arterial line. We thereby attempt to cover the specific individual fluid deficit induced by neuroaxial blockade.

Official Title
-----------------
Neuroaxial Blokade and the Effect of Fluid Optimization

Conditions
-----------------
Hypovolemia

Intervention / Treatment
-----------------
* Procedure: Stroke volume optimization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Neuroaxial blockade (thoracic) Exclusion Criteria: Weight below 40 kg Lithium therapy Type I diabetes or type II requiring insulin

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Stroke volume optimization|Stroke volume optimization|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stroke volume |  | 15 min after blockade | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Brain oxygenation, cardiac output, TPR, NIRS, BP |  | 15 min after blockade |
Ocular Imaging Study Using Advanced OCT

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate this AngioScan angiography software on patients with various retinal vascular disorders. The advanced OCT instrument is an FDA approved clinically used camera, but the AngioScan angiography software is not FDA approved. Investigators would like to know if this imaging device and software can improve the quality of images and visualization of imaged tissues and whether they are useful in the diagnosis and treatment of eye diseases. Images collected in this study may be compared to other images collected as part of standard of care on the same patient (OCT, FA, AF, Fundus).

Official Title
-----------------
Ocular Imaging Study Using Advanced OCT

Conditions
-----------------
Retinal Vascular Disorder, Macular Degeneration

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • Any patient with abnormal retinal findings as determined by investigators. Exclusion Criteria: Those suffering from head, neck or other injury which makes them unable to position themselves in head restraint for imaging. Participants who are unable to maintain retinal fixation on a specified target. Participants unable to achieve sufficient pupil dilation and alignment stability for imaging to take place. Patients with media opacity which preclude high quality imaging.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 115 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Retina abnormalities<br>Subjects with various retina vascular disorders | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retinal vascular abnormalities imaged by OCT Angiography and en face analysis of macular disorders |  | 2 years |
What is the Prevalence of Female Pelvic Floor Disorders in Minnesota?

Study Overview
=================
Brief Summary
-----------------
To determine the prevalence of pelvic organ prolapse and urinary incontinence among women in Minnesota using a short web-based self-administered questionnaire.

Detailed Description
-----------------
The study will be administered at the 2018 Minnesota State Fair at the Driven to Discover building. The study will be administered entirely for research purposes. All data will be self-reported (see attached survey). Data collection will be through a web-based version of the EPIQ loaded into Research Electronic Data Capture REDCap, a secure web-based system for data collection. Data collection will occur over 6 half day sessions at the University of Minnesota D2D building at the Minnesota State Fair Grounds while the Fair is running.

Official Title
-----------------
D2D What is the Prevalence of Female Pelvic Floor Disorders in Minnesota?

Conditions
-----------------
Prolapse, Urinary Incontinence, Fecal Incontinence, Bladder Pain Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women who are age 18 or older on the date they take the survey who are willing to take the survey. Pregnant women may participate in the survey. Exclusion Criteria: Inability to provide consent to take the survey, and inability to speak and understand English.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prolapse | Prevalence of prolapse in the population studied | Aug-Sep 2018 | 
| Urinary incontinence | Prevalence of urinary incontinence in the population studied | Aug-Sep 2018 | 
| Fecal incontinence | Prevalence of fecal incontinence in the population studied | Aug-Sep 2018 | 
| Bladder pain | Prevalence of bladder pain in the population studied | Aug-Sep 2018 |
A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer

Study Overview
=================
Brief Summary
-----------------
A study of Raltitrexed plus Docetaxel versus Docetaxel as second-line chemotherapy in subjects with Gastric Cancer.The purpose of this study is to compare the activity of Raltitrexed plus Docetaxel versus Docetaxel as second-line chemotherapy in subjects with gastric carcinoma by estimating progression free survival (PFS) in each treatment arm.

Official Title
-----------------
A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer

Conditions
-----------------
Gastric Cancer

Intervention / Treatment
-----------------
* Drug: Raltitrexed plus Docetaxel
* Drug: Docetaxel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed informed consent form Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-2; Histologically or cytologically confirmed gastric cancer; The first-line chemotherapy failure (required containing 5-fluorouracil) At least have one measurable disease(according to RECIST, Response Evaluation Criteria in Solid Tumors ) Life expectancy of at least 3 months; Exclusion Criteria: Received any prior treatment including Raltitrexed; Active or uncontrolled infection; Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial; Pregnant or lactating women.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Raltitrexed plus Docetaxel<br> | Drug: Raltitrexed plus Docetaxel<br>* Raltitrexed plus Docetaxel (Raltitrexed 3mg/m2 d 1; Docetaxel 75mg/m2 d1, every 3 weeks, 4-6 cycles)<br>|
| Active Comparator: Docetaxel<br> | Drug: Docetaxel<br>* Docetaxel (Docetaxel 75mg/m2 d1, every 3weeks,4-6 cycles)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival (PFS) |  | 1 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective Response Rate (ORR) |  | 1 year | 
| Overall Survival (OS) |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
second-line chemotherapy, Raltitrexed
Effect of Dental Scaling on Helicobacter Pylori Eradication and Reinfection

Study Overview
=================
Brief Summary
-----------------
Patients who had received H.pylori eradication treatment will be categorised as eradication and reinfection status and whether dental scaling has any influence on these results.

Detailed Description
-----------------
Patients over 18 years with no comorbidities especially liver, cardiac and haemorrhagic diathesis and giving informed consent will be categorised according to their status of dental scaling, eradication and reinfection rates of h.pylori. Statistical examination will include the multiple regression and Chi-Square. The result will emphasize the influence of dental scaling on eradication (Presence of Hp cure 1-6 months after treatment) and reinfection ( reappearance of Hp 12 months later than the treatment).

Official Title
-----------------
Effect of Dental Scaling on Helicobacter Pylori Eradication and Reinfection

Conditions
-----------------
Helicobacter Pylori Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 18 with h.pylori positivity and received anti-Hp treatment giving informed consent to analyse of their data on this subject. Exclusion Criteria: Comorbidities with cardiac, liver and medical contraindication to perform dental scaling.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with scaling and patients without scaling<br>No drug | |
| Helicobacter eradicated or non-eradicated<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The eradication and reinfection rates in dental scaled and non-scaled patients. |  | last 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reinfection rate of patients treated for H.pylori |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Helicobacter pylori, Dental scaling, Eradication, Reinfection, Helicobacter status
Turning Performance in Stroke

Study Overview
=================
Brief Summary
-----------------
Turning is a challenging task for stroke patient. Previous studies showed that turning is one of the activities which resulting in falling frequently in stroke. However, the assessment tool of turning performance is still lack of reliability and validity. Furthermore, the main factors which affected turning ability in stroke are not approved yet.

Official Title
-----------------
Evaluation and Improving Strategy of Turning Performance in Individuals With Stroke

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Behavioral: turning task


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 6 months after first stroke. Able to independently walk 7 meter at least without any device MMSE score ≧ 24 Exclusion Criteria: Unstable medical conditions (such as deep vein thrombosis) Any disease which has known affecting walk(heart failure, diabetes)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy<br> | Behavioral: turning task<br>* Several trials included bilateral turning in 30, 60, 90, 120, 150, 180 degree.<br>|
| Stroke<br> | Behavioral: turning task<br>* Several trials included bilateral turning in 30, 60, 90, 120, 150, 180 degree.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Turning angle |  | 10 minutes | 
| Turning time |  | 10 minutes | 
| Turning step |  | 10 minutes | 
| Single leg supported time during turning |  | 10 minutes | 
| Swing time during turning |  | 10 minutes |
A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess REN001 safety in subjects with primary mitochondrial myopathy

Official Title
-----------------
An Open-label Study to Evaluate the Safety and Tolerability of 12 Weeks Treatment With Oral REN001 in Patients With Primary Mitochondrial Myopathy (PMM), With an Optional Extension of Treatment

Conditions
-----------------
Primary Mitochondrial Myopathy

Intervention / Treatment
-----------------
* Drug: REN001


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects must give written, signed and dated informed consent Confirmed diagnosis of PMM according to the 2016 Rome Consensus recommendations Confirmed mitochondrial mutation with evidence of myopathy Able to remain on stable medication throughout the study Exclusion Criteria: Documented evidence of ongoing rhabdomyolysis Subjects with motor abnormalities other than related to mitochondrial disease Treatment with an investigational drug within 3 months prior to Day 1 Hospitalised within 3 months prior to screening for any major medical condition Pregnant or nursing females

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group<br>REN001 Low Dose | Drug: REN001<br>* Once daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse Events | Number of participants with Adverse Events as a measure of safety and tolerability | Comparing Baseline to Week 12 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse Events | Number of participants with Adverse Events as a measure of safety and tolerability | Continous to Week 48 |